(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 3.6MM | +3% |
Gross Profit | 132K | -78% |
Cost Of Revenue | 3.5MM | +20% |
Operating Income | -14.2MM | -9% |
Operating Expenses | 14.3MM | -11% |
Net Income | -14.3MM | -9% |
R&D | 4.2MM | -26% |
G&A | 5.5MM | +34% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees beginning in the third quarter of 2024.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando. The first study provides an analysis of member data for those tracking a GLP-1 medication in Dario's cardiometabolic solution.
While the innovation sphere constantly focuses on artificial intelligence these days, the top players in the field have gotten a lot of attention – maybe too much attention. Recently, we’ve seen the mighty Nvidia (NASDAQ:NVDA) lose a step from its previously mercurial ways. And that may open the doors for considering small-cap AI stocks to buy. Let’s get the bad news out of the way first. Betting on small-capitalization firms of any sector presents higher risks than wagering on established enter
DarioHealth Corp. (Nasdaq: DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability.
Discover how DarioHealth Corp (DRIO) is shaping its future with significant B2B2C growth, high gross margins, and strategic partnerships in the first quarter of 2024.
DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the first quarter 2024.
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.